Biomarkers for PLC activity are currently under investigation. Phosphorylation status of PLC isoforms and levels of downstream effectors like DAG and IP3 can serve as potential biomarkers. For example, elevated levels of phosphorylated PLCγ1 have been correlated with aggressive breast cancer. Additionally, genetic mutations or amplifications of PLC genes can be detected using genomic sequencing techniques.